At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 68 enrolled
Drug / intervention
Xtandidrug
Likely dose
Xtandi 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano·interventional·Posted Apr 6, 2017·Updated Apr 26, 2021
In Brief
A Phase 2 clinical trial evaluating Xtandi for Carcinoma Prostate. Completed, enrolled 68 participants across 1 site.
Detailed Summary
Open label, single arm, phase II multicentre study designed to determine the clinical benefit, as measured by 3-months disease control rate (DCR) provided by enzalutamide in metastatic Castration Resistant Prostate Cancer patients with at least one visceral site involvement.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma Prostate
CountriesItaly
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMar 2017
First PostedApr 2017
Primary CompletionApr 2021
TodayJul 2026
First PostedApr 6, 2017
Enrollment StartMar 16, 2017
Primary CompletionApr 23, 2021
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 9.2 years ago
Interventions
Xtandidrug
Enzalutamide 160 mg (4 x 40 mg capsules), orally once daily